Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future
- François-Joseph L. MuratAffiliated withUrology and Transplantation Department, Edouard Herriot Hospital Email author
- , Albert Gelet
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Based on a review of recently published articles, we evaluated the current status of high-intensity focused ultrasound (HIFU) as a primary treatment option for localized prostate cancer and as a salvage therapy when radiation has failed. With mid-and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 90%, and an excellent morbidity profile, primary HIFU appears to be a valid alternative to active surveillance protocols in low-risk patients and standard therapies in patients with life expectancies of 10 or fewer years. Moreover, HIFU has a considerable potential for local-only recurrence after radiation failure. HIFU is a recent technology, and many improvements will undoubtedly expand its future indications and use for the management of prostate cancer.
- Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future
Current Urology Reports
- Online Date
- May 2008
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors